Tecan Group AG · SIX:TECN
Tecan — Tecan Symposium 2010
38 slides from Tecan's conference presentation, 2010
Slide 1: Naked gene vaccines
„Naked“ gene Titel vaccines DNA RNA Plasmid “backbone” antibiotic resistance plasmid antigen ori CMV promoter
Slide 2: Principles of gene vaccines
Principles ofTitel gene vaccines Injection of genetic information Transfection – episomal transcription Expression of the gene product Simulation of a „danger“ signal Induction of immunity
Slide 3: Transcription and transfection
Transcription Titel and transfection Messenger RNA Plasmid “backbone” antibiotic resistance plasmid antigen ori CMV promoter
Slide 4: Translation
Translation Titel Protein tRNA-AS mRNA Protein (Vaccine)
Slide 5: Inherent adjuvantation
Inherent adjuvant“ation“ Titel Plasmid “backbone” antibiotic resistance plasmid antigen ori CMV promoter Plasmid DNA activates TLR-9 Immune stimulation TLR-9 induces IL-12 in APCs Immune polarization IL-12 polarizes Th0 Zellen
Slide 6: Processing and presentation
Processing and presentation Titel Plasmid DNA IgG B SC Th Th APC CTL IC Induction of cellular and humoral immune responses 1992 1993 Nature Science S.Johnston J.Ulmer
Slide 7: Unique features: controlled modulation
Titel Unique features: controlled modulation „Talk with the immune system“ Secretion Intracellular expression Membran integration Co-expression of „orders“
Slide 8: Application modes
Application Titel modes Mouse: Needle (i.m., i.d.) Gene gun (e.d.) Human: Needle (i.m., i.d.) Electroporation Jet injection Biojector
Slide 9: The beginning
The „beginning“ Titel Walter Reed Army Institute Malaria Gene Vaccines J. Lyon, W.W. Leitner National Institutes of Health Tumor Mini-Gene Vaccines S. Abrams, E.S. Bergmann Research Centre Vienna Borreliosis Gene Vaccines I. Livey, F.Dorner,
Slide 10: The anti-allergic potential of DNA vaccines
The „anti-allergic“ potential Titel of DNA vaccines Collaboration with F. Ferreira SC IFN- Th1 APC Hartl et al. (1999, JACI)
Slide 11: The allergic immune response
The „allergic“ immune response Titel Mucus MC GC IL-5, IL-13 MC Eos Th2 IgE Allergen B IL-4 Th2 APC
Slide 12: Allergy versus DNA vaccine
Allergie „versus“ DNA vaccine Titel MC GC IL-5, IL-13 MC Eos Plasmid DNA Th2 IgE Allergen B IL-4 IgG B SC Th2 Th1 IFN- Th1 APC APC CTL IC
Slide 13: The anti-allergic module-principle of gene vaccines
The „anti-allergic“ Module 5 -principle Titel of Mucus DNA vaccines Gene Vaccines MC GC IL-5, IL-13 MC Eos Plasmid DNA Th2 IgE Allergen B IL-4 IgG B SC Th2 Th1 IFN- Th1 APC APC CTL CTL IC
Slide 14: Protective and therapeutic treatment of allergy
Protective and therapeutic Titel treatment of allergy Th1 Proof of concept: CTL Hartl A. et al., J.Allergy Clin.Immunology 1999, 103:107-113 Weiss, R. et al., Vaccine 2002, 20:3148 Hochreiter, R. et al., J. Allergy Clin. Immunol. 2003, 112:579-584. Hochreiter, R. et al., Eur. J. Immunol. 2003, 33:16
Slide 15: Why vaccination?
Titel Why „vaccination“ ? • Prevention is superior to any therapeutic treatment • Priming of a naive immune system is easy • Conversion of a running response is difficult BUT • Allergy is not life-threatening • Healthy kids will be immunized
Slide 16: Arguments for vaccination
ArgumentsTitel for vaccination Steady increase of allergic diseases Gene vaccines lost their „mysterious“ image Pediatricians changed their attitude Allergic parents want to protect their children Compliance is increasing
Slide 17: Benefits of gene vaccines
Benefits ofTitel gene vaccines Benefits of gene vaccines • they are allergen-specific without sensitization potential (unique) • they are highly defined, clean and safe vaccines • their principles of action are known to a great extent • they enable rapid application of new knowledge
Slide 18: A basic experiment - prevention from allergic sensitization (IgE)
A basic experiment - prevention from Titel allergic sensitization (IgE) Bet v 1a (birch) Test 0 7 14 21 28 35 42 49 56 63 70 ................92 Genetic immunization with pCMV-Bet (i.d.) Challenge with rBet (sensitization, s.c.) Hartl A. et al., J.Allergy Clin.Immunology 1999, 103:107-113
Slide 19: IgE (day 92)
IgE (day Titel92) ELISA RBL-Release
Slide 20: Proliferation and IFN-gamma (day 92)
Proliferation and IFN- (day 92) Titel Th1 Th1 Th1 Th1 Th1
Slide 21: Prevention from lung inflammation
Prevention fromTitel lung inflammation Goblet cell hyperplasia proliferation of bronch/vasc endothelium A) B) 70 50 % g o b let cell m etap lasia bronchial 60 vascular % K i-67 p o s. cells 40 50 40 30 30 20 20 10 10 0 0 M 5 co P5 l M 5 pC 5 l M 5 co P5 l M 5 pC 5 l co V co V ro ro ro ro pC n-P pC n
Slide 22: Prevention from lung inflammation
Prevention fromTitel lung inflammation Eosinophilia in BALF IL-5 in BALF A) B) 90 200 % eosinophils in BAL 80 175 70 150 IL-5 [pg/m l] 60 125 50 100 40 75 30 20 50 10 25 0 0 n a ro l n a ro l na o l na o l nt V co M V M -P5 nt 5 p ive M -P5 pC-P5 e M -P5 nt 5 pS e M -P5 pC P5 e coV-P co -P iv iv iv
Slide 23: The protective principle
The protective Titel principle Recruitment of Th1 cells decision horizone Th1 Th1 Th1 Th1 Th1 Th1 Th1 Th1 Th1 Th1
Slide 24: The protective principle
The protective Titel principle Sensitization Macrophage Dendritic cell B cell Th1 Th1 Th1 Th1 Th1 IFN- Th1 Th1 Th1 Th1 Th1 Th1 milieu
Slide 25: From mouse to men
From mouse to men Titel
Slide 26: Requirements for human use
Requirements for human use Titel “Minimal” vaccine No antibiotic resistance genes No genomic integration No induction of autoimmunity No induction of anti-DNA antibodies Short-lived vaccine/expression
Slide 27: Requirements for human use
Requirements for human use Titel “Minimal” vaccine RNA No antibiotic resistance genes No genomic integration No induction of autoimmunity No induction of anti-DNA antibodies Short-lived vaccine/expression
Slide 28: Mechanism
Mechanism Titel Injection Transfection Translation
Slide 29: Evaluation
Evaluation Titel 1. challenge i.n. 1.im m unizatio n 2. challenge i.n. 2. im m unizatio n 1.sensitizatio n 3. challenge i.n. 3. im m unizatio n 2. sensitizatio n WB P 0 10 20 30 40 50 60 70 sacrifice serum pre serum po st
Slide 30: RNA vaccines are immunogenic, Th1-stimulating and protect from Th2 responses
RNA Vaccines are immunogenic, Titel TH1-stimulating and protect from Th2 responses 3500000.0 A 2000000 B IgG1 Serum=1:100 IgG1 Serum=1:10 000 3000000.0 IgG2a IgG2a 2500000.0 1500000 2000000.0 ** ** ** RLU RLU 1000000 * * 1500000.0 ** ** ** ** ** ** ** 1000000.0 ** * 500000 ** 500000.0 ** ** * 0.0 0
Slide 31: RNA vaccines induce Th1 cells and inhibit IL-4, 5 and 13
IL5-secreting cells / 10 6 IFNg-secreting cells / 10 6 0 50 0 100 150 200 100 200 300 400 500 600 ** P 5-RNA 40 P 5-RNA 40 ** A C P 5-RNA 8 P 5-RNA 8 ** ** P 5-RNA 1.6 P 5-RNA 1.6 P 5-repRNA 8 P 5-repRNA 8 ** ** P 5-repRNA 1.6 P 5-repRNA 1.6 ** ** P 5-repRNA 0.32 P 5-repRNA 0.32 control control naiv
Slide 32: RNA vaccines protect from eosinophilia and AHR
RNA vaccines protect from eosinophilia und AHR Titel
Slide 33: RNA vaccines against pollen allergens
RNA vaccines against pollen allergens Titel Encoded Type of Allergen IgG2ac IFN- d IgE e IgE f Allergen b induction prevention Pollen allergen Aln g 1 Alder + n.s. ++ - - Amb a 1 Short ragweed - + - n.d. Bet v 1 Birch ++ ++ - ++ Car b 1 European hornbeam ++ +++ - +++ Cas s 1 Chestnut ++ +++ - +++ C
Slide 34: RNA vaccines against food, animals, moulds and latex
RNA vaccines against food, animals, moulds and latex Titel Encoded Type of Allergen IgG2ac IFN- d IgE e IgE f Allergen b induction prevention Food allergens Api g 1 Celery + +++ - ++ Ara h 2.02 Peanut + n.s. +++ n.s. - n.d. -Casein Milk - +/- - n.d. Cyp c 1.01 Carp +/- - - n.d. Dau c 1 Carrot +++
Slide 35: Cross-induction of Th1 cells
„Cross-induction“ of Th1 cells (IFN- Titel Aln g 1 (alder) Cor a 1 (hazel) Api g 1 (celery) Dau c 1 (carrot) Bet v 1a (white birch) Fag s 1 (beech) Car b 1 (hornbeam) Mal d 1 (apple) Cas s 1 (chestnut) Que a 1 (white oak) Aln RNA Cor RNA Mal RNA 1.00 1.00 2.0 Vaccinated Vaccinated Vaccinated Nai
Slide 36: Conclusion
Conclusion Titel RNA vaccines protect against allergic sensitization RNA vaccines are allergen-specific RNA vaccines are cross-protective RNA vaccines are hypo-allergenic RNA vaccines cannot integrate into the genom (non-gene therapy classified by FDA) RNA vaccines are real „minimal“ vaccines (no ad
Slide 37: Just one step from the goal
Just one step from the goal Titel
Slide 38: Acknowledgements
Acknowledgements Titel Richard Weiss, Peter Hammerl, Sandra Scheiblhofer, Angelika Stöcklinger, Lisa Rösler, Esther Weinberger, Tatjana Stepanoska, Hannes Freund, Katharina Tobias, Gudrun Horner, Andrea Autengruber Arnulf Hartl, Max Gabler, Roman Bauer, Martin Gaisberger, Verena Faltis, Theresa Thal